Minimal Residual Disease Testing in Multiple Myeloma
Abstract
As myeloma therapies achieve unprecedented depth and durability of response, accurate measurement of residual disease—through validated MRD testing, with next-generation sequencing offering some practical and sensitivity advantages over next-generation flow cytometry—has become essential to guide prognosis, treatment duration, and the emerging possibility of functional cure in multiple myeloma.
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Chronic Lymphocytic Leukemia Research
Multiple Sclerosis Research Studies
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 5 March 2026
- Language
- EN
- Document type
- Dataset